ReviewJournal of clinical laboratory analysis2026
Biomarkers of Endothelial Damage in Acute Graft-Versus-Host Disease After Allogenic Hematopoietic Stem Cell Transplantation: Methodological Challenges.
Review in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundAcute graft-versus-host disease (aGVHD) is a major complication following allogeneic hematopoietic stem cell transplantation. The current diagnostic approach relies primarily on clinical manifestations and histopathological evaluation of affected tissues. Consequently, there is an urgent need to identify minimally invasive biomarkers that provide predictive, diagnostic, or prognostic value, as well as utility in monitoring therapeutic responses. In particular, biomarkers that enable early identification of patients unresponsive to treatment are highly warranted.
methodsThis article reviews research on aGVHD biomarkers, with a particular focus on those related to endothelial damage. Data published between 2004 and 2025 were sourced from PubMed, Google Scholar, and ScienceDirect using the following keywords: acute graft versus host disease, endothelial damage, biomarkers, circulating endothelial cells, endothelial progenitor cells, microRNA, extracellular vesicles, serum biomarkers, enzyme-linked immunosorbent assay, flow cytometry, and analytical errors. This article reviews the findings, with a specific focus on the analytical challenges associated with their determination and the potential for their implementation in clinical settings.
resultsRecent advances in high-throughput methodologies have led to the identification of potential biomarkers for aGVHD. Growing evidence indicates that endothelial damage contributes to this complication, especially in treatment-resistant patients. In addition to soluble serum biomarkers, other promising candidates such as circulating endothelial cells, extracellular vesicles, and microRNAs have been identified. However, the methodologies for their assessment have not yet been standardized.
conclusionsFuture efforts should focus on standardizing these methods and establishing comprehensive biomarker panels, as none of the biomarkers identified so far are entirely specific to aGVHD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.